WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease. Th…
Category: Business
Avedro annonce le recrutement du premier patient dans l’essai pivot de phase 3 épi-on sur la réticulation cornéenne pour le kératocône progressif aux États-Unis
WALTHAM, Massachusetts–(BUSINESS WIRE)–Avedro, Inc., une société de produits pharmaceutiques ophtalmiques et d’appareils médicaux qui est aussi le leader mondial du remodelage de la cornée, a annoncé aujourd’hui avoir démarré le recrutement de patients dans le cadre d’un essai clinique pivot de Phase 3 visant à évaluer l’innocuité et l’efficacité d’un procédé de réticulation du collagène de la cornée épithélium-on (épi-on) pour traiter les patients atteints d’un kératocône progressif. Le kéra
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus
WALTHAM, Mass.–(BUSINESS WIRE)–#crosslinking–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial t…
Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of William Coppola as Intellectual Property Counsel, reporting to John LaRocca, Aerie’s General Counsel. Mr. Coppola will oversee intellectual property matters both domestically and
Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences announces new interim data from Phase 1b/2 study of light-activated AU-011 for the treatment of primary choroidal melanoma.
Global Ophthalmic Ultrasound Systems Market Outlook 2017-2026, With an Expected CAGR of 8% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Ultrasound Systems – Global Market Outlook (2017-2026)” report has been added to ResearchAndMarkets.com’s offering. According to the publisher, the Global Ophthalmic Ultrasound Systems Market is accounted for $2…
Cataract Surgery Devices: Global Market Report 2018-2023 – Market is Projected to Reach $9 Billion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Cataract Surgery Devices Market Analysis (2017-2023)” report has been added to ResearchAndMarkets.com’s offering. Cataract Surgery Devices Market was valued at $7 billion in 2016, and is estimated to reach $9 billio…
Cataract Surgery Devices: Global Market Report 2018-2023 – Market is Projected to Reach $9 Billion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Cataract Surgery Devices Market Analysis (2017-2023)” report has been added to ResearchAndMarkets.com’s offering. Cataract Surgery Devices Market was valued at $7 billion in 2016, and is estimated to reach $9 billio…
Mevion Medical Systems Successfully Completes Growth Financing; Well Positioned for Global Expansion
LITTLETON, Mass.–(BUSINESS WIRE)–#cancercare–Mevion Medical Systems has successfully completed growth financing for global expansion.
Optovue Announces Expanded FDA Clearance of Epithelial Thickness Mapping
FREMONT, Calif.–(BUSINESS WIRE)–Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), today announced an expanded FDA 510(k) clearance for non-contact, quantitative measurements of the epithel…
Health and Eye Care Industry Leader Philip Isham Joins Eye Health America as Chief Development Officer
ATLANTA–(BUSINESS WIRE)–Eye Health America (EHA), the leader in full-service eye care, has named Philip Isham, eye care strategist and executive, as Chief Development Officer
Ocular Hypertension Drug Development Pipeline Study, H1 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension: Drug Development Pipeline Study, H1 2018” report has been added to ResearchAndMarkets.com’s offering. Ocular Hypertension report identifies aspects important in modifying industry market scenarios, inc…
Ocular Hypertension Drug Development Pipeline Study, H1 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension: Drug Development Pipeline Study, H1 2018” report has been added to ResearchAndMarkets.com’s offering. Ocular Hypertension report identifies aspects important in modifying industry market scenarios, inc…
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that it has entered an exclusive agreement with the University of Florida Research Foundation and the University of Pennylvania.
Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Digital Pathology Market Report 2018 – FPNV Positioning Matrix & Vendor Profiles – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Digital Pathology Market – FPNV Positioning Matrix & Vendor Profiles” report has been added to ResearchAndMarkets.com’s offering. The positioning of the digital pathology market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefr
SeniorWell Announces New Hire to Legal Team
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced the hiring of The Honorable Camela Gardner to SeniorWell’s legal team.
Achromatopsia: 2018 Pipeline Analysis by Company, Phase, Molecule Type, and Route of Administration – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Achromatopsia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments” report has been added to ResearchAndMarkets.com’s offering. This repor…
Fabry’s Disease: Global Pipeline Analysis 2018 – Covering 20 Drugs Currently in Different Phases of Development – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Fabry’s Disease Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments” report has been added to ResearchAndMarkets.com’s offering. The report prov…
Des nouvelles données de l’essai IMCgp100-102 montrent une réponse durable et un robuste taux de survie globale chez les patients atteints d’un mélanome uvéal métastatique
OXFORD, Angleterre, et CONSHOHOCKEN, Pennsylvanie–(BUSINESS WIRE)–Les patients atteints de mélanome uvéal métastatique (MUm) traités par IMCgp100 continuent d’obtenir une réponse tumorale durable avec un suivi médian de 19,1 mois, sans atteindre la survie globale (SG) médiane, selon une nouvelle étude de phase I qui doit être présentée aujourd’hui à Chicago, lors de la réunion annuelle de l’American Society of Clinical Oncology (ASCO).2 IMCgp100 est le programme phare détenu en totalité par I